Wells Fargo analyst David Maris maintained a Buy rating on Amphastar Pharmaceuticals (AMPH) today. The company’s shares closed on Friday at $21.94, close to its 52-week high of $22.74.
According to TipRanks.com, Maris ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.9% and a 32.5% success rate. Maris covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals Plc, Bausch Health Companies Inc, and Emergent Biosolutions.
Currently, the analyst consensus on Amphastar Pharmaceuticals is a Strong Buy with an average price target of $24.
See today’s analyst top recommended stocks >>
Based on Amphastar Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $2.39 million. In comparison, last year the company had a net profit of $1.47 million.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. Most recently, in December 2018, Stephen Shohet, a Director at AMPH sold 58,557 shares for a total of $1,271,272.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.
